Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors

Purpose: This was an open-label phase 1a study assessing the maximum tolerated dose (MTD), safety, and tolerability of CXCR4 peptide antagonist, LY2510924, administered in combination with durvalumab in patients with advanced refractory solid tumors. Methods: Patients received LY2510924 at 20, 30, o...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Pancreat Cancer
Asıl Yazarlar: O'Hara, Mark H., Messersmith, Wells, Kindler, Hedy, Zhang, Wei, Pitou, Celine, Szpurka, Anna M., Wang, Dan, Peng, Sheng-Bin, Vangerow, Burkhard, Khan, Anis A., Koneru, Mythili, Wang-Gillam, Andrea
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Mary Ann Liebert, Inc., publishers 2020
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7097682/
https://ncbi.nlm.nih.gov/pubmed/32219196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/pancan.2019.0018
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller